🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
VRTX
NASDAQ
🇺🇸 US
Vertex Pharmaceuticals Incorporated
Pharmaceuticals
24Score
DipBuster Score™
$472.57
$9.43 (-1.96%)
Live price · Source: Yahoo
52-Week Position
$362.50
64% of range
$533.67
Beta
0.292
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.292
52W High$533.67
52W Low$362.50
DipBuster Brief
Key signals at a glance
Zone: Hold / Watch
Neutral
Mid-Range Position (64% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position64% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.292
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Vertex Pharmaceuticals Incorporated (VRTX), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-07-15 | Sachs Bruce I | BUY | 100 |
| 2026-07-02 | Mckechnie Duncan | SELL | 1,541 |
| 2026-07-02 | Tatsis Ourania | SELL | 1,500 |
| 2026-07-01 | Liu Joy | SELL | 828 |
| 2026-06-18 | Bozic Carmen | SELL | 1,020 |
| 2026-06-05 | Bozic Carmen | SELL | 1,745 |
| 2026-06-01 | Liu Joy | SELL | 828 |
| 2026-05-29 | Bozic Carmen | SELL | 1,974 |
| 2026-05-15 | Bunnage Mark E. | SELL | 33 |
| 2026-05-15 | Bozic Carmen | SELL | 1,354 |
Graham NCAV Analysis
Above net-net level
Current Assets$11.20B
Less: Total Liabilities−$6.98B
= Net Current Asset Value$4.22B
NCAV Per Share$16.6297
Current Price$480.15
Price / NCAV28.87×
Margin of Safety-2787.3%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.292
Dividend/yrNone
52W High$533.67
52W Low$362.50
52-Week Range
$362.50Now$533.67
64% through annual range
From 52W High−11.4%
From 52W Low+30.4%
📖 Plain English Summary
Vertex Pharmaceuticals Incorporated is at 64% of its 52-week range. Beta 0.292 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for VRTX
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — VRTX
Heuristic · balance sheet, insider filings, price data, academic research
Vertex Pharmaceuticals Incorporated — DipBuster Score 24/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Vertex Pharmaceuticals Incorporated free
Add VRTX to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
14/25
Momentum & Volume
5/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
20
/100 · NEUTRAL
dip depth
8/25
oversold rsi
4/25
mean reversion
9/15
insider zone
0/25
capitulation
0/10
Insiders' avg buy price: $389.61 — marked 🟡 on the chart above.
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 24/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a ran…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Reshma Kewalramani
Staff
6,400 employees
Website